Physician profile
Carlos E Ballestas
NPI 1609812437
$12,118.48
in general payments reported to CMS, 2019-2025
42 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,130 · 2020: $2,251 · 2021: $1,738 · 2022: $770 · 2023: $1,006 · 2024: $2,351 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,229.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,691.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,306.63 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $880.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $854.06 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $729.79 | 2019-2025 | Zepbound, Mounjaro |
| Amgen INC. | $542.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $506.77 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $493.25 | 2019-2024 | Xarelto |
| Abbvie INC. | $478.23 | 2019-2025 | Synthroid |
| Merck Sharp & Dohme LLC | $455.37 | 2019-2025 | Capvaxive, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $340.02 | 2019-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $318.29 | 2023-2025 | |
| Astellas Pharma US INC | $298.37 | 2023-2025 | Veozah |
| Amarin Pharma, INC. | $267.74 | 2019-2021 | |
| Exact Sciences Corporation | $245.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Ballestas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.